Literature DB >> 20858707

Selective transport of monoamine neurotransmitters by human plasma membrane monoamine transporter and organic cation transporter 3.

Haichuan Duan1, Joanne Wang.   

Abstract

The plasma membrane monoamine transporter (PMAT) and organic cation transporter 3 (OCT3) are the two most prominent low-affinity, high-capacity (i.e., uptake(2)) transporters for endogenous biogenic amines. Using the Flp-in system, we expressed human PMAT (hPMAT) and human OCT3 (hOCT3) at similar levels in human embryonic kidney 293 cells. Parallel and detailed kinetics analysis revealed distinct and seemingly complementary patterns for the two transporters in transporting monoamine neurotransmitters. hPMAT is highly selective toward serotonin (5-HT) and dopamine, with the rank order of transport efficiency (V(max)/K(m)) being: dopamine, 5-HT ≫ histamine, norepinephrine, epinephrine. The substrate preference of hPMAT toward these amines is substantially driven by large (up to 15-fold) distinctions in its apparent binding affinities (K(m)). In contrast, hOCT3 is less selective than hPMAT toward the monoamines, and the V(max)/K(m) rank order for hOCT3 is: histamine > norepinephrine, epinephrine > dopamine >5-HT. It is noteworthy that hOCT3 demonstrated comparable (≤2-fold difference) K(m) toward all amines, and distinctions in V(max) played an important role in determining its differential transport efficiency toward the monoamines. Real-time reverse transcription-polymerase chain reaction revealed that hPMAT is expressed at much higher levels than hOCT3 in most human brain areas, whereas hOCT3 is selectively and highly expressed in adrenal gland and skeletal muscle. Our results suggest that hOCT3 represents a major uptake(2) transporter for histamine, epinephrine, and norepinephrine. hPMAT, on the other hand, is a major uptake(2) transporter for 5-HT and dopamine and may play a more important role in transporting these two neurotransmitters in the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20858707      PMCID: PMC2993547          DOI: 10.1124/jpet.110.170142

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

Review 1.  Plasma membrane monoamine transporters: structure, regulation and function.

Authors:  Gonzalo E Torres; Raul R Gainetdinov; Marc G Caron
Journal:  Nat Rev Neurosci       Date:  2003-01       Impact factor: 34.870

2.  Cloning and functional characterization of a potential-sensitive, polyspecific organic cation transporter (OCT3) most abundantly expressed in placenta.

Authors:  R Kekuda; P D Prasad; X Wu; H Wang; Y J Fei; F H Leibach; V Ganapathy
Journal:  J Biol Chem       Date:  1998-06-26       Impact factor: 5.157

Review 3.  Perspectives on the discovery of central monoaminergic neurotransmission.

Authors:  A Carlsson
Journal:  Annu Rev Neurosci       Date:  1987       Impact factor: 12.449

Review 4.  Role of transmitter uptake mechanisms in synaptic neurotransmission.

Authors:  L L Iversen
Journal:  Br J Pharmacol       Date:  1971-04       Impact factor: 8.739

Review 5.  Neurotransmitter transporters: recent progress.

Authors:  S G Amara; M J Kuhar
Journal:  Annu Rev Neurosci       Date:  1993       Impact factor: 12.449

Review 6.  Regulation of the adrenal medulla.

Authors:  A Ungar; J H Phillips
Journal:  Physiol Rev       Date:  1983-07       Impact factor: 37.312

7.  Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.

Authors:  Frank P Bymaster; Jason S Katner; David L Nelson; Susan K Hemrick-Luecke; Penny G Threlkeld; John H Heiligenstein; S Michelle Morin; Donald R Gehlert; Kenneth W Perry
Journal:  Neuropsychopharmacology       Date:  2002-11       Impact factor: 7.853

8.  The dopamine inhibitor GBR 12909: selectivity and molecular mechanism of action.

Authors:  P H Andersen
Journal:  Eur J Pharmacol       Date:  1989-08-03       Impact factor: 4.432

9.  The effect of various ions on uptake2 of catecholamines.

Authors:  H Bönisch; L J Bryan; M Henseling; S R O'Donnell; P Stockmann; U Trendelenburg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-02       Impact factor: 3.000

Review 10.  Molecular physiology of norepinephrine and serotonin transporters.

Authors:  R D Blakely; L J De Felice; H C Hartzell
Journal:  J Exp Biol       Date:  1994-11       Impact factor: 3.312

View more
  81 in total

1.  Electrophysiological characterization of the polyspecific organic cation transporter plasma membrane monoamine transporter.

Authors:  Shiro Itagaki; Vadivel Ganapathy; Horace T B Ho; Mingyan Zhou; Ellappan Babu; Joanne Wang
Journal:  Drug Metab Dispos       Date:  2012-03-06       Impact factor: 3.922

2.  Common drugs inhibit human organic cation transporter 1 (OCT1)-mediated neurotransmitter uptake.

Authors:  Kelli H Boxberger; Bruno Hagenbuch; Jed N Lampe
Journal:  Drug Metab Dispos       Date:  2014-03-31       Impact factor: 3.922

3.  Decynium-22 enhances SSRI-induced antidepressant-like effects in mice: uncovering novel targets to treat depression.

Authors:  Rebecca E Horton; Deana M Apple; W Anthony Owens; Nicole L Baganz; Sonia Cano; Nathan C Mitchell; Melissa Vitela; Georgianna G Gould; Wouter Koek; Lynette C Daws
Journal:  J Neurosci       Date:  2013-06-19       Impact factor: 6.167

Review 4.  Concepts of scientific integrative medicine applied to the physiology and pathophysiology of catecholamine systems.

Authors:  David S Goldstein
Journal:  Compr Physiol       Date:  2013-10       Impact factor: 9.090

5.  Molecular analysis and structure-activity relationship modeling of the substrate/inhibitor interaction site of plasma membrane monoamine transporter.

Authors:  Horace T B Ho; Yongmei Pan; Zhiyi Cui; Haichuan Duan; Peter W Swaan; Joanne Wang
Journal:  J Pharmacol Exp Ther       Date:  2011-08-04       Impact factor: 4.030

Review 6.  The SLC22 Transporter Family: A Paradigm for the Impact of Drug Transporters on Metabolic Pathways, Signaling, and Disease.

Authors:  Sanjay K Nigam
Journal:  Annu Rev Pharmacol Toxicol       Date:  2018-01-06       Impact factor: 13.820

7.  Impact of Substrate-Dependent Inhibition on Renal Organic Cation Transporters hOCT2 and hMATE1/2-K-Mediated Drug Transport and Intracellular Accumulation.

Authors:  Jia Yin; Haichuan Duan; Joanne Wang
Journal:  J Pharmacol Exp Ther       Date:  2016-10-06       Impact factor: 4.030

8.  Impaired monoamine and organic cation uptake in choroid plexus in mice with targeted disruption of the plasma membrane monoamine transporter (Slc29a4) gene.

Authors:  Haichuan Duan; Joanne Wang
Journal:  J Biol Chem       Date:  2012-12-19       Impact factor: 5.157

9.  Tetramethylpyrazine analogue CXC195 protects against cerebral ischemia/reperfusion-induced apoptosis through PI3K/Akt/GSK3β pathway in rats.

Authors:  Lin Chen; Xinbing Wei; Yunfeng Hou; Xiaoqian Liu; Senpeng Li; Baozhu Sun; Xinyong Liu; Huiqing Liu
Journal:  Neurochem Int       Date:  2014-01-22       Impact factor: 3.921

10.  Potent and Selective Inhibition of Plasma Membrane Monoamine Transporter by HIV Protease Inhibitors.

Authors:  Haichuan Duan; Tao Hu; Robert S Foti; Yongmei Pan; Peter W Swaan; Joanne Wang
Journal:  Drug Metab Dispos       Date:  2015-08-18       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.